| Literature DB >> 21092191 |
Javier Muñiz1, Juan J Gómez-Doblas, María I Santiago-Pérez, Iñaki Lekuona-Goya, Nekane Murga-Eizagaetxebarría, Eduardo de Teresa-Galván SS, José M Cruz-Fernández, Alfonso Castro-Beiras.
Abstract
OBJECTIVES: We investigated whether an intervention mainly consisting of a signed agreement between patient and physician on the objectives to be reached, improves reaching these secondary prevention objectives in modifiable cardiovascular risk factors six-months after discharge following an acute coronary syndrome.Entities:
Mesh:
Substances:
Year: 2010 PMID: 21092191 PMCID: PMC3002321 DOI: 10.1186/1477-7525-8-137
Source DB: PubMed Journal: Health Qual Life Outcomes ISSN: 1477-7525 Impact factor: 3.186
Objectives and indicators
| Objectives | Indicators |
|---|---|
| Giving up smoking | % of patients who gave up smoking |
| Having BMI < 25 | % of patients with BMI ≥ 25 who reduced it by at least 10% |
| Doing regular exercise | % of patients who do physical exercise at least three times a week for at least 20/30 minutes |
| Controlling lipid levels | % of patients with total cholesterol < 175 mg/dl |
| Controlling hypertension | % of patients with hypertension who have had their blood pressure controlled since discharge |
| Taking prescribed medication | % of patients taking AAS (6 months) when prescribed at discharge |
Comparison of Basal Characteristics of Intervention and Control Groups*
| Intervention | Control | p-value | |
|---|---|---|---|
| Males | 77.7 | 75.6 | 0.301 |
| Age (years old) (mean ± sd) | 62.1 ± 11.6 | 63.6 ± 11.4 | 0.007 |
| Present diagnosis AMI | 65.9 | 64.6 | 0.304 |
| Family history of ischemic cardiomyopathy | 18.7 | 17.9 | 0.657 |
| Certain previous diagnosis of ischemic cardiomyopathy | 31.5 | 29.1 | 0.276 |
| Personal history: | |||
| Stroke | 4.8 | 6.4 | 0.156 |
| Peripheral arteriopathy | 8.8 | 9.3 | 0.683 |
| Renal failure | 5.3 | 5.8 | 0.624 |
| Arterial hypertension | 58.9 | 60.1 | 0.616 |
| Hypercholesterolemia | 51.4 | 50.7 | 0.748 |
| Diabetes | 25.3 | 29.6 | 0.044 |
| Obesity | 31.3 | 34.2 | 0.195 |
| Smokers | 33.3 | 26.1 | 0.001 |
| BMI (kg/m2) (average ± sd) | 28.2 ± 4.2 | 28.3 ± 4.3 | 0.627 |
| BMI ≥ 30 kg/m2 | 29.6 | 30.4 | 0.932 |
| Abdominal perimeter (men/women) ≥ 102/88 cm | 47.8 | 51.8 | 0.172 |
| Abdominal perimeter (men/women) ≥ 94/80 cm | 74.0 | 74.3 | 0.929 |
* Results expressed as % unless otherwise indicated
Figure 1Flow-chart of follow-up of patients included in trial.
Degree of Achievement of Objectives at Six Months in Both Groups
| Objectives (nI/nC) | Intervention | Control | Adjustedγ | Adjusted OR | p-value |
|---|---|---|---|---|---|
| Given up smoking (253/200) | 76.3 | 71.0 | 1.25 | 0.81-1.94 | 0.309 |
| BMI ≥ 25 kg/m2 (567/547) | |||||
| < 25 kg/m2 | 9.9 | 7.8 | 1.21 | 0.79-1.86 | 0. 373 |
| ⇓ BMI ≥ 10% | 7.4 | 6.8 | 1.15 | 0.72-1.84 | 0.564 |
| ⇓ BMI ≥ 5% | 25.0 | 19.7 | 1.31 | 0.98-1.76 | 0.068 |
| BMI ≥ 30 kg/m2 (212/209) | |||||
| < 30 kg/m2 | 25.9 | 24.9 | 1.04 | 0.66-1.63 | 0.860 |
| ⇓ BMI ≥ 10% | 11.3 | 10.5 | 1.15 | 0.61-2.17 | 0.666 |
| ⇓ BMI ≥ 5% | 32.1 | 27.8 | 1.26 | 0.82-1.93 | 0.300 |
| Changes in BMI (average) (kg/m2)* | - 0.5 | - 0.2 | 0.35* | 0.16-0.55* | < 0.001 |
| Changes in abdominal perimeter (average) (cm)* | - 1.6 | - 0.6 | 1.03* | 0.00-2.06* | 0.05 |
| Exercise 5 times/week | 29.4 | 23.4 | 1.29 | 1.02-1.64 | 0.033 |
| Exercise 3 times/week | 48.4 | 41.0 | 1.29 | 1.05-1.59 | 0.017 |
| Cholesterol < 175 md/dl | 64.7 | 56.5 | 1.46 | 1.17-1.81 | 0.001 |
| LDL < 100 mg/dl (70 in diabetic patients) | 47.9 | 44.8 | 1.09 | 0.87-1.35 | 0.449 |
| BP < 135/80 mmHg (130/80 in diabetic patients) | 46.7 | 42.4 | 1.14 | 0.91-1.41 | 0.253 |
| Taking of medication (percentage who take it on final visit, out of total given medication on discharge from hospital) | |||||
| Aspirin (712/698) | 97.5 | 96.0 | 1.54 | 0.84-2.83 | 0.161 |
| Clopidogrel (571/533) | 72.9 | 74.3 | 0.91 | 0.69-1.20 | 0.499 |
| Beta-blockers (621/590) | 94.4 | 94.6 | 0.93 | 0.56-1.54 | 0.769 |
| ACE-inhibitors (400/387) | 86.8 | 84.0 | 1.31 | 0.87-1.98 | 0.192 |
| Angiotensin receptor blocking agent Type II (ARA II) (86/97) | 84.9 | 86.6 | 0.83 | 0.35-1.95 | 0.664 |
| Statins (677/635) | 98.1 | 95.9 | 0.83 | 0.35-1.95 | 0.029 |
Results in intervention and control columns expressed as % of total number of patients affected by this objective as indicated in the first column, unless otherwise indicated
γ Differences in means (ANOVA model) or odds ratios [OR, logistic regression] adjusted for age group, education level, history of stroke, medication for cholesterol and tobacco consumption prior to admission, variables with statistical significant differences at baseline in the group of patients included in this analysis. Reference group for all estimates: control group). See interpretation of OR in the results section.
* In these continuous outcome variables, (changes in body mass index [BMI] and abdominal perimeter) the coefficients of the ANOVA model adjusted for the same variables, instead of odds ratios, are presented.
nI/nC: Number of patients in intervention/control groups on which the percentages presented are based when they are not the same as the total indicated in the corresponding column.
CI: Confidence interval